MA49653A - Efficacité d'une forme posologique d'agent séquestrant d'acide biliaire à rétention gastrique - Google Patents

Efficacité d'une forme posologique d'agent séquestrant d'acide biliaire à rétention gastrique

Info

Publication number
MA49653A
MA49653A MA049653A MA49653A MA49653A MA 49653 A MA49653 A MA 49653A MA 049653 A MA049653 A MA 049653A MA 49653 A MA49653 A MA 49653A MA 49653 A MA49653 A MA 49653A
Authority
MA
Morocco
Prior art keywords
effectiveness
dosage form
gastric retention
acid sequestrant
biliary acid
Prior art date
Application number
MA049653A
Other languages
English (en)
Inventor
Mark G Currie
Michael Hall
Ahmad Hashash
Silva Karasik
Bernard Joseph Lavins
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of MA49653A publication Critical patent/MA49653A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA049653A 2017-07-19 2018-07-19 Efficacité d'une forme posologique d'agent séquestrant d'acide biliaire à rétention gastrique MA49653A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762534591P 2017-07-19 2017-07-19
US201862681633P 2018-06-06 2018-06-06

Publications (1)

Publication Number Publication Date
MA49653A true MA49653A (fr) 2021-05-19

Family

ID=65015306

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049653A MA49653A (fr) 2017-07-19 2018-07-19 Efficacité d'une forme posologique d'agent séquestrant d'acide biliaire à rétention gastrique

Country Status (9)

Country Link
US (2) US20230190662A1 (fr)
EP (1) EP3654953A4 (fr)
JP (1) JP2020527580A (fr)
CN (2) CN114767646A (fr)
AU (1) AU2018302255A1 (fr)
BR (1) BR112020001071A2 (fr)
CA (1) CA3070082A1 (fr)
MA (1) MA49653A (fr)
WO (2) WO2019018639A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110579541B (zh) * 2019-08-29 2022-04-08 北京悦康科创医药科技股份有限公司 一种兰索拉唑有关物质的检测方法
CN110596295A (zh) * 2019-10-21 2019-12-20 上海百趣生物医学科技有限公司 一种检测胆汁酸的方法
CN111005074A (zh) * 2019-12-19 2020-04-14 江西海普洛斯医学检验实验室有限公司 一种基于illumina测序平台的DNA文库构建试剂盒、文库构建方法和应用
CN111060643B (zh) * 2020-01-16 2021-04-02 博莱克科技（武汉）有限公司 一种含有同分异构体胆汁酸代谢组分分离方法
CN111812264B (zh) * 2020-07-09 2021-06-15 苏州旭辉检测有限公司 一种去氧胆酸类化合物的生物样品分析方法
CN114235995A (zh) * 2021-12-03 2022-03-25 天津国科医工科技发展有限公司 检测血清中15种胆汁酸的方法
CN115201357A (zh) * 2022-06-17 2022-10-18 陕西盘龙医药研究院 一种小儿咽扁颗粒中猪去氧胆酸的限量检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158625A2 (fr) * 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions et procédés de traitement ou de prévention des troubles gastro-intestinaux et des troubles respiratoires liés à gerd
US20120009130A1 (en) * 2010-05-06 2012-01-12 Nanoaxis Viral Therapy and Prophylaxis Using Nanotechnology Delivery Techniques
WO2011157655A1 (fr) * 2010-06-15 2011-12-22 Biocrates Life Sciences Ag Utilisation des acides de la bile pour la prédiction d'une apparition de sepsie
US20130156720A1 (en) * 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CA2826506C (fr) * 2011-02-04 2017-07-25 Biocopea Limited Compositions et methodes pour traiter l'inflammation chronique et les maladies inflammatoires
CN102729224B (zh) * 2012-07-05 2016-04-27 南京德朔实业有限公司 具有辅助弹出电池包功能的电动工具
AU2014207680B2 (en) * 2013-01-15 2018-09-06 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
WO2016126625A1 (fr) * 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Méthodes de traitement de troubles gastro-intestinaux supérieurs de gerd réfractaire à ppi
EP3362060A4 (fr) * 2015-10-18 2019-06-19 Wei Jia Biomarqueurs associés au diabète et de traitement d'affections associées au diabète

Also Published As

Publication number Publication date
EP3654953A1 (fr) 2020-05-27
WO2019018656A1 (fr) 2019-01-24
AU2018302255A1 (en) 2020-02-06
CN111050755A (zh) 2020-04-21
JP2020527580A (ja) 2020-09-10
BR112020001071A2 (pt) 2020-07-14
WO2019018639A1 (fr) 2019-01-24
US20230190662A1 (en) 2023-06-22
CN114767646A (zh) 2022-07-22
EP3654953A4 (fr) 2021-05-19
CA3070082A1 (fr) 2019-01-24
US20200138854A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
MA49653A (fr) Efficacité d'une forme posologique d'agent séquestrant d'acide biliaire à rétention gastrique
MA49045A (fr) Compositions et procédés destinés à la distribution régulée d'acide
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
MA48779A (fr) Formes cristallines d'inhibiteur de fgfr et leurs procédés de préparation
JP2017506627A5 (fr)
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
MA52942A (fr) Composés inhibiteurs d'oga
MA47179A (fr) Composition d'acide dicarboxylique mannuronique
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA50155A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
IL272309B (en) Amino acid compounds for the treatment of liver disease
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA47420A (fr) Composés inhibiteurs d'oga
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EA201890694A1 (ru) Группа соединений, применяющихся для лечения или предупреждения гиперурикемии или подагры
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA49704A (fr) Dérivés d'acide biliaire à marquage isotopique
FR3049601B1 (fr) Procede ameliore de production d'acide (meth)acrylique
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
MA42614A (fr) Dérivés d'acide 5-(n-benzyl tétrahydroisoquinolin-6-yl) pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
MA47203A (fr) Inhibiteurs d'antiport à médiation par nhe
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta